Safety analysis: relative risks of ultraviolet exposure from fluorescence spectroscopy and colposcopy are comparable.
Fluorescence spectroscopy is a promising tool for use in the diagnosis of disease in human tissue. However, few published reports have evaluated the safety of this technique, despite the fact that many spectroscopic systems use UV illumination. This study determined the relative risk associated with light exposure from spectroscopic systems compared with the traditional light sources that are used to illuminate tissue and direct biopsies. We compared spectroscopic detection systems for the cervix to the colposcope, a low-power microscope routinely used to illuminate the cervix, which does not cause any known photochemical damage. We measured the average spectral irradiance (W/[cm2nm]) and the average tissue exposure time during a diagnostic colposcopy examination. To quantify the relative risks, we multiplied illumination spectra by several action spectra from the literature and compared the areas under the curves corresponding to each procedure. The risk associated with the average power colposcope served as our basis for comparison. We conclude that the risks of illumination using spectroscopic systems are lower than or comparable to those already encountered in routine diagnostic procedures such as colposcopy with an average power colposcope. Spectroscopic examination can be associated with a somewhat higher risk than a colposcopy with the lowest power colposcope or a shorter than average colposcopy. The analysis presented can be repeated to estimate the magnitude of risks associated with other spectroscopic diagnostic devices.
Brookner
C K
CK
Biomedical Engineering Program, University of Texas at Austin, USA.
Agrawal
A
A
Trujillo
E V
EV
Mitchell
M F
MF
Richards-Kortum
R R
RR
D003127:Colposcopy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D011230:Precancerous Conditions / Q000175:diagnosis; D018570:Risk Assessment; D013050:Spectrometry, Fluorescence; D014466:Ultraviolet Rays / Q000009:adverse effects*; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis